ArriVent BioPharma Q2 EPS $(0.65) Misses $(0.54) Estimate
Portfolio Pulse from Benzinga Newsdesk
ArriVent BioPharma (NASDAQ:AVBP) reported a Q2 EPS of $(0.65), missing the analyst consensus estimate of $(0.54) by 20.37%. This represents a significant improvement from the $(10.79) per share loss in the same period last year.
August 14, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ArriVent BioPharma reported a Q2 EPS of $(0.65), missing the analyst estimate of $(0.54) by 20.37%. However, this is a significant improvement from the $(10.79) per share loss in the same period last year.
The missed EPS estimate is likely to have a negative short-term impact on the stock price. However, the significant improvement from last year's loss may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100